Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
| ▸ | GABRE | P78334 | 2/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29509647 | 0.92 | MAPK1 (0.49) | MAPK1LCKKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4000060 | 0.92 | MAPK1 (0.49) | MAPK1LCKKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL25446545 | 0.92 | MAPK1 (0.43) | MAPK1LCKKDM4EALDH1A1GABRP | |
| SCHEMBL22462518 | 0.90 | MAPK1 (0.42) | MAPK1LCKKDM4EALDH1A1GABRP | |
| SCHEMBL17979291 | 0.87 | LCK (0.45) | MAPK1LCKKDM4EALDH1A1GABRP | |
| SCHEMBL2054682 | 0.87 | MAPK1 (0.43) | MAPK1LCKKDM4EALDH1A1GABRP | |
| SCHEMBL3716193 | 0.86 | ALDH1A1 (0.48) | MAPK1LCKKDM4EALDH1A1GABRP | |
| SCHEMBL792511 | 0.86 | MAPK1 (0.42) | MAPK1LCKKDM4EALDH1A1GABRP | |
| SCHEMBL2130286 | 0.86 | ALDH1A1 (0.44) | MAPK1LCKKDM4EALDH1A1GABRP | |
| SCHEMBL18125980 | 0.86 | MAPK1 (0.42) | MAPK1LCKKDM4EALDH1A1GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891386-B2 | Indole compounds and their use | ARIAGEN, INC. (CA) | 2024-02-06 | — | — | US | disclosed |
| EP-3774770-B1 | NOVEL HYDRAZONE DERIVATIVES FOR PREVENTING OR TREATING EBV-RELATED CANCERS | UNIV BRETAGNE OCCIDENTALE (FR) | 2023-09-06 | — | — | EP | disclosed |
| US-20230145074-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145074-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230054194-A1 | Methods of Treating Cancer | ARIAGEN, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230054194-A1 | Methods of Treating Cancer | ARIAGEN, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11459322-B2 | Indole compounds and their use | ARIAGEN, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11459322-B2 | Indole compounds and their use | ARIAGEN, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11427576-B2 | Indole compounds and their use | ARIAGEN, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11406631-B2 | Hydrazone derivatives for preventing or treating EBV-related cancers | UNIVERSITE DE BRETAGNE OCCIDENTALE | 2022-08-09 | — | — | US | disclosed |
| WO-2007079199-A2 | SUBSTITUTED BIS-AMIDE METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, HOLDING, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| WO-2006083454-A1 | MULTICYCLIC BIS-AMIDE MMP INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | ALANTOS PHARMACEUTICALS, INC., | 2006-08-03 | — | — | US | disclosed |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | US | disclosed |
| US-20030229103-A1 | PYRIDINE-2,4-DICARBOXYLIC ACID DIAMIDES AND PYRIMIDINE-4,6-DICARBOXYLIC ACID DIAMIDES AND THE USE THEREOF FOR SELECTIVELY INHIBITING COLLAGENASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| US-5130317-A | Immunosuppressants and fibrosuppressants for metabolism of collagen | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229103-A1 | PYRIDINE-2,4-DICARBOXYLIC ACID DIAMIDES AND PYRIMIDINE-4,6-DICARBOXYLIC ACID DIAMIDES AND THE USE THEREOF FOR SELECTIVELY INHIBITING COLLAGENASES | DPYD, MMP13, MMP2 | MAPK1 1423/4885LCK 3060/4885KDM4E 1108/4885 |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | MMP13, DPYD, MMP1 | MAPK1 730/4885LCK 3238/4885KDM4E 582/4885 |
| US-11459322-B2 | Indole compounds and their use | IDO1, IDO2, INMT | MAPK1 3004/4885LCK 17/4885KDM4E 1007/4885 |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | MMP13, MMP3, MMP11 | MAPK1 1940/4885LCK 4747/4885KDM4E 1633/4885 |
| US-11427576-B2 | Indole compounds and their use | IDO1, IDO2, INMT | MAPK1 3004/4885LCK 17/4885KDM4E 1007/4885 |
| US-11891386-B2 | Indole compounds and their use | IDO1, IDO2, INMT | MAPK1 3004/4885LCK 17/4885KDM4E 1007/4885 |
| US-20230054194-A1 | Methods of Treating Cancer | TP53, MSH2, PDCD1 | MAPK1 4068/4885LCK 35/4885KDM4E 1153/4885 |
| US-11406631-B2 | Hydrazone derivatives for preventing or treating EBV-related cancers | RB1, MALT1, NR3C1 | MAPK1 2066/4885LCK 3653/4885KDM4E 2112/4885 |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | MAPK1 2151/4885LCK 4073/4885KDM4E 1084/4885 |
| US-20230145074-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | MAPK1 3004/4885LCK 17/4885KDM4E 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.